Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2016 1
2017 1
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab for melanoma- safety profile and future trends.
Daud A, Nandoskar P. Daud A, et al. Among authors: nandoskar p. Expert Opin Drug Saf. 2016 Jun;15(6):727-9. doi: 10.1080/14740338.2016.1175430. Epub 2016 Apr 27. Expert Opin Drug Saf. 2016. PMID: 27056241 No abstract available.
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. Algazi AP, et al. Among authors: nandoskar p. Pigment Cell Melanoma Res. 2018 Jan;31(1):110-114. doi: 10.1111/pcmr.12644. Epub 2017 Nov 2. Pigment Cell Melanoma Res. 2018. PMID: 28921907 Free PMC article. Clinical Trial.